Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Gastro-enteropancreatic neuroendocrine tumor × 3-Iodobenzylguanidine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Gastrointestinal 1 Endocrine 1

Conditions

Neuroendocrine Tumors 2 Pheochromocytoma 1 Paraganglioma 1 Neuroblastoma 1 Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

regorafenib 1 lutetium Lu 177 dotatate 1 irinotecan sucrosofate 1 PM 01183 1 Irinotecan 1 Clinical Trials, Phase II as Topic 1 Carboplatin 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04614766 2024-04-29

SPORE-3

University of Iowa

Phase 1/2 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡